Context Therapeutics Inc., (Nasdaq-CNTX) a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells express... Context Therapeutics Inc., (Nasdaq-CNTX) a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Show more
PHILADELPHIA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (βContextβ or the βCompanyβ) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today...
Announced acquisition of CT-95, a mesothelin x CD3 bispecific antibody Claudio Dansky Ullmann, M.D. named Chief Medical Officer Cash and cash equivalents of $101.5 million as of June 30, 2024...
Company announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations Appointments support the development of the Companyβs two clinical-stage T...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.22 | 10.7843137255 | 2.04 | 2.5 | 1.94 | 331276 | 2.23115115 | CS |
4 | -0.21 | -8.5020242915 | 2.47 | 2.62 | 1.94 | 145523 | 2.25831109 | CS |
12 | 0.28 | 14.1414141414 | 1.98 | 2.75 | 1.7301 | 108497 | 2.2452237 | CS |
26 | 1.06 | 88.3333333333 | 1.2 | 2.75 | 1.17 | 420123 | 1.88204099 | CS |
52 | 1.18 | 109.259259259 | 1.08 | 2.75 | 0.77 | 232195 | 1.81158539 | CS |
156 | -2.18 | -49.0990990991 | 4.44 | 10.87 | 0.47 | 779935 | 3.76125909 | CS |
260 | -2.18 | -49.0990990991 | 4.44 | 10.87 | 0.47 | 779935 | 3.76125909 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.